Abiomed (ABMD) 24.64 $ABMD
ABIOMED's Impella RP Bags CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:50PM CDT
Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.
Abiomed Acquires Exclusive License for Opsens' Optical Sensor Technology
GlobeNewswire - Tue Apr 15, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its acquisition of an exclusive license from collaboration partner Opsens (TSX-V:OPS), a leading developer of fiber optic sensors. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella(R) heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab.
Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Magellan Health Services Inc. (NASDAQ: MGLN), ABIOMED, Inc. (NASDAQ: ABMD), CONMED Corporation (NASDAQ: CNMD), and Greatbatch, Inc. (NYSE: GB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1143-100free
Abiomed Fourth Quarter Fiscal 2014 Earnings and Conference Call Notification
GlobeNewswire - Thu Apr 10, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, May 1, 2014, the Company will release financial results for the fourth quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, May 1, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.
Abiomed Receives CE Mark for Impella RP
GlobeNewswire - Tue Apr 08, 8:40AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received CE Marking approval in the European Union to market the Impella(R) RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure.
Balanced View on Haemonetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 1:50PM CDT
On Mar 28, we issued an updated research report on Haemonetics Corporation.
Balanced View on Hologic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 1:50PM CDT
On Mar 27, we issued an updated research report on Hologic.
Study: Teleflex Catheter Reduces Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:20PM CDT
The study, conducted by Leonardo Lorente M.D., Ph.D. and his colleagues independently, found that the Teleflex's ARROW catheter with ARROWg+ard Blue PLUS Technology lowers the risk of catheter-related bloodstream infections.
Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will be attending and exhibiting at the American College of Cardiology (ACC) annual 2014 scientific sessions, scheduled from March 29 - 31, at the Walter E. Washington Convention Center in Washington, DC.
Facility Investments, Earnings Release Schedules, Definitive Agreements, Patient Enrollments, and Clinical Trial Updates - Analyst Notes on Novo Nordisk, HealthSouth, AMRI, Abiomed, and Geron
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ: ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ABIOMED's Impella Trial Achieves Enrollment Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 2:20PM CDT
On reaching the enrollment target, ABIOMED plans to submit the compiled data and seek FDA approval for a Continuous Access Protocol.
Teleflex Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 12:35PM CDT
Shares of Teleflex started escalating following its impressive 2013-fourth quarter results and promising 2014 guidance as well as its recent 510(k) clearance from U.S. Food and Drug Administration.
Upgrade Alert for ABIOMED (ABMD)
Comtex SmarTrend(R) - Fri Mar 21, 8:00AM CDT
ABIOMED (NASDAQ:ABMD) was upgraded from Neutral to Buy at BTIG today. The stock closed yesterday at $26.20 on volume of 579,000 shares, above average daily volume of 425,000. ABIOMED (NASDAQ:ABMD) has potential upside of 8.4% based on a current price of $26.20 and analysts' consensus price target of $28.40. The stock should hit resistance at its 50-day moving average (MA) of $27.87, as well as support at its 200-day MA of $24.65.
What Makes Tenet (THC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:54AM CDT
It may be a good decision to sell Tenet as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Impella Maintains Existing Diagnosis Related Groups (DRGs) Assignment With Updated ICD-10 Coding Issued by the Centers for Medicare & Medicaid Services (CMS)
GlobeNewswire - Fri Mar 21, 7:10AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Centers for Medicare & Medicaid Services (CMS) has released an updated version of ICD-10 MS-DRGs (version 31R) and maintained assignment to Diagnosis Related Groups (MS-DRGs) 216-221 for the category of devices that includes Impella(R) pumps.
FDA Clears Volcano Corp's iFR Modality - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 4:10PM CDT
Volcano Corporation recently received the U.S. FDA approval for the company's proprietary iFR (instant wave-Free Ratio) Modality.
Abiomed Completes Patient Enrollment in RECOVER RIGHT Impella Study
GlobeNewswire - Thu Mar 20, 7:14AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the completion of the 30th patient enrolled in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella(R) RP (Right Peripheral). The trial was designed to enroll as many as 30 patients, at 15 sites, for up to 14 days of circulatory support.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Mar 20, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Breakthrough for Luminex's xMAP Technology - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:20PM CDT
Luminex's xMAP Technology will be deployed by the HPA project to perform flexible and high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples.
Teleflex Gets 510(k) Clearance for Restated Indications - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:00PM CDT
EZ-IO Vascular Access System has been developed by Vidacare Corporation, acquired by Teleflex in December last year.
ABIOMED's Impella RP Bags CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:50PM CDT
Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.
Abiomed Acquires Exclusive License for Opsens' Optical Sensor Technology
GlobeNewswire - Tue Apr 15, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its acquisition of an exclusive license from collaboration partner Opsens (TSX-V:OPS), a leading developer of fiber optic sensors. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella(R) heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab.
Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Magellan Health Services Inc. (NASDAQ: MGLN), ABIOMED, Inc. (NASDAQ: ABMD), CONMED Corporation (NASDAQ: CNMD), and Greatbatch, Inc. (NYSE: GB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1143-100free
Abiomed Fourth Quarter Fiscal 2014 Earnings and Conference Call Notification
GlobeNewswire - Thu Apr 10, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, May 1, 2014, the Company will release financial results for the fourth quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, May 1, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.
Abiomed Receives CE Mark for Impella RP
GlobeNewswire - Tue Apr 08, 8:40AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received CE Marking approval in the European Union to market the Impella(R) RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure.
Balanced View on Haemonetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 1:50PM CDT
On Mar 28, we issued an updated research report on Haemonetics Corporation.
Balanced View on Hologic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 1:50PM CDT
On Mar 27, we issued an updated research report on Hologic.
Study: Teleflex Catheter Reduces Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:20PM CDT
The study, conducted by Leonardo Lorente M.D., Ph.D. and his colleagues independently, found that the Teleflex's ARROW catheter with ARROWg+ard Blue PLUS Technology lowers the risk of catheter-related bloodstream infections.
Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will be attending and exhibiting at the American College of Cardiology (ACC) annual 2014 scientific sessions, scheduled from March 29 - 31, at the Walter E. Washington Convention Center in Washington, DC.
Facility Investments, Earnings Release Schedules, Definitive Agreements, Patient Enrollments, and Clinical Trial Updates - Analyst Notes on Novo Nordisk, HealthSouth, AMRI, Abiomed, and Geron
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ: ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ABIOMED's Impella Trial Achieves Enrollment Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 2:20PM CDT
On reaching the enrollment target, ABIOMED plans to submit the compiled data and seek FDA approval for a Continuous Access Protocol.
Teleflex Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 12:35PM CDT
Shares of Teleflex started escalating following its impressive 2013-fourth quarter results and promising 2014 guidance as well as its recent 510(k) clearance from U.S. Food and Drug Administration.
Upgrade Alert for ABIOMED (ABMD)
Comtex SmarTrend(R) - Fri Mar 21, 8:00AM CDT
ABIOMED (NASDAQ:ABMD) was upgraded from Neutral to Buy at BTIG today. The stock closed yesterday at $26.20 on volume of 579,000 shares, above average daily volume of 425,000. ABIOMED (NASDAQ:ABMD) has potential upside of 8.4% based on a current price of $26.20 and analysts' consensus price target of $28.40. The stock should hit resistance at its 50-day moving average (MA) of $27.87, as well as support at its 200-day MA of $24.65.
What Makes Tenet (THC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:54AM CDT
It may be a good decision to sell Tenet as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Impella Maintains Existing Diagnosis Related Groups (DRGs) Assignment With Updated ICD-10 Coding Issued by the Centers for Medicare & Medicaid Services (CMS)
GlobeNewswire - Fri Mar 21, 7:10AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Centers for Medicare & Medicaid Services (CMS) has released an updated version of ICD-10 MS-DRGs (version 31R) and maintained assignment to Diagnosis Related Groups (MS-DRGs) 216-221 for the category of devices that includes Impella(R) pumps.
FDA Clears Volcano Corp's iFR Modality - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 4:10PM CDT
Volcano Corporation recently received the U.S. FDA approval for the company's proprietary iFR (instant wave-Free Ratio) Modality.
Abiomed Completes Patient Enrollment in RECOVER RIGHT Impella Study
GlobeNewswire - Thu Mar 20, 7:14AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the completion of the 30th patient enrolled in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella(R) RP (Right Peripheral). The trial was designed to enroll as many as 30 patients, at 15 sites, for up to 14 days of circulatory support.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Mar 20, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Breakthrough for Luminex's xMAP Technology - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:20PM CDT
Luminex's xMAP Technology will be deployed by the HPA project to perform flexible and high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples.
Teleflex Gets 510(k) Clearance for Restated Indications - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:00PM CDT
EZ-IO Vascular Access System has been developed by Vidacare Corporation, acquired by Teleflex in December last year.
